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Key points  
• There is more cost-effectiveness evidence on pharmacological therapies 
than other interventions. Acetylcholinesterase inhibitors for mild-to-
moderate disease and memantine for moderate-to-severe disease were 
found to be cost-effective.  
• Regarding non-pharmacological treatments, cognitive stimulation therapy, 
tailored activity programme and occupational therapy were found to be 
more cost-effective than usual care. 
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• There was some evidence to suggest that respite care in day settings and 
psychosocial interventions for carers could be cost-effective, as could 
coordinated care management.  
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Structured abstract  
Objective: 
We reviewed evidence on the cost-effectiveness of prevention, care and 
treatment strategies in relation to dementia.  
Methods: 
We performed a systematic review of available literature on economic 
evaluations of dementia care, searching key databases and websites in 
medicine, social care and economics. Literature reviews were privileged, and 
other study designs included only to fill gaps in the evidence base. Narrative 
analysis was used to synthesise the results.  
Results: 
We identified 56 literature reviews and 29 single studies offering economic 
evidence on dementia care. There is more cost-effectiveness evidence on 
pharmacological therapies than other interventions. Acetylcholinesterase 
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inhibitors for mild-to-moderate disease and memantine for moderate-to-severe 
disease were found to be cost-effective. Regarding non-pharmacological 
treatments, cognitive stimulation therapy, tailored activity programme and 
occupational therapy were found to be more cost-effective than usual care. 
There was some evidence to suggest that respite care in day settings and 
psychosocial interventions for carers could be cost-effective. Coordinated care 
management and personal budgets held by carers have also demonstrated 
cost-effectiveness in some studies.  
Conclusion: 
Five barriers to achieving better value for money in dementia care were 
identified: the scarcity and low methodological quality of available studies; the 
difficulty of generalising from available evidence; the narrowness of cost 
measures; a reluctance to implement evidence; and the poor coordination of 
health and social care provision and financing.
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Introduction 
 
Anticipated upward trends in the number of people with dementia will lead to 
substantial increases in health and social care spending unless provision is 
altered or there are major breakthroughs in prevention or disease course 
(Comas-Herrera et al., 2007). Coupled with an anticipated downward trend in 
the availability of (unpaid) carer support – and in a context of macroeconomic 
austerity – governments and health and social care funding bodies are looking 
for ways to maintain – better still to improve – the quality and coverage of care 
without increasing levels of spending. What, then, is known about the cost-
effectiveness of prevention, care and treatment strategies in relation to 
dementia? We performed a systematic review of available literature, 
privileging literature reviews. 
 
Methods 
 
A systematic literature review was performed searching key databases and 
websites in medicine, social care and economics. Electronic searches were 
conducted in February 2011 of numerous databases: PubMed/Medline, 
Embase, PsycINFO, EconLit, the Cochrane Library (Cochrane Reviews), and 
the Centre for Reviews and Dissemination (Database of Abstracts of Reviews 
and Effects, NHS Economic Evaluation Database, Health Technology 
Assessment). We looked at these websites: the database of the National 
Institute for Health and Clinical Excellence (NICE), the Social Care Institute 
for Excellence (SCIE), the National Audit Office, the Royal College of 
 5 
Psychiatrists, the Royal College of General Practitioners, the Alzheimer’s 
Society, the King’s Fund, Carers UK, the Mental Health Foundation, Age UK, 
and the Bradford Dementia Group. 
 
Key words used for the search were ‘dementia’, ‘Alzheimer’s disease’, 
‘vascular dementia’ combined with ‘cost’, ‘hospital’ and ‘home care’. Specific 
types of dementia beyond Alzheimer’s disease were searched for: ‘dementia 
with Lewy bodies’, ‘dementia in Parkinson's disease’, ‘dementia in human 
immunodeficiency virus (HIV) disease’. Rare types of dementia linked to 
metabolic or neurological disorders were not specifically searched for but 
were not excluded, such as ‘dementia in Pick's disease’, ‘dementia in 
Huntington's disease’, ‘dementia in Creutzfeldt-Jakob disease’, ‘dementia in 
other specified diseases classified elsewhere’, and ‘unspecified dementia’.  
 
Searches were limited to items published from 2005 onwards for databases, 
and from 2000 onwards for websites. We searched for papers with title and 
abstract available in English; and full-text in English, French, Spanish or 
Italian. The inclusion criteria were studies focused on evaluating interventions 
for people with dementia or their carers which reported evidence on service 
use or costs, conducted in high-income countries. All study designs were 
considered: quantitative, qualitative, mixed methods, economic evaluations, 
systematic interventions targeted on people with mild cognitive impairment 
(MCI) which did not lead to a dementia diagnosis. We first screened titles and 
abstracts for relevance (according to the inclusion criteria) and then obtained 
the full text of included articles. 
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Narrative analysis was used to synthesise the results. All eligible papers were 
included. We grouped the papers into four categories: 
• pharmacological interventions; 
• non-pharmacological interventions for individuals with dementia; 
• interventions for carers of individuals with dementia; and 
• organisation of care and support. 
Literature reviews were privileged, and other study designs included 
only to fill gaps in the evidence base. Details of the search strategy are 
available on request from the authors. 
 
Results 
 
After removal of duplicates, 2305 references were identified. Then, the 
screening by title and summary led to 329 potentially relevant references. 
Finally, the screening by full-text resulted in 56 included in the final literature 
review. 29 single studies were considered in order to fill the gap in the 
evidence presented in the 56 literature review. Figure 1 illustrates the study 
selection process. Meta-analysis was not performed due to the heterogeneity 
of the studies. 
 
<Figure 1> 
 
Pharmacological interventions 
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The majority of the economic evidence was on pharmacological interventions 
aimed at alleviating behavioural, cognitive and functional symptoms. A 
particular interest in the literature is the possibility of slowing down the 
progression of the disease. From an economic standpoint, this has the 
potential to reduce carer burden, lessen the rate of hospitalization and delay 
long-term admission into institutional care, where costs often increase 
dramatically (Fillit, 2005; Fillit and Hill, 2005). The majority of cost-
effectiveness-studies found in our review focused on drugs for Alzheimer’s 
disease. 
 
Acetylcholinesterase Inhibitors (AChEI) and memantine 
 
Most of the literature reviews concerned acetylcholinesterase inhibitors 
(AChEI) and memantine. NICE (2011) recently updated its technology 
appraisal guidance on the use of acetylcholinesterase inhibitors and 
memantine for Alzheimer’s disease (National Institute for Health and Clinical 
Excellence, 2006, 2009). Published economic evaluations since 2004 were 
systematically reviewed by NICE, and results presented by severity of 
disease. For mild-to-moderate Alzheimer’s disease, it was concluded that 
AChEI (donepezil, rivastigmine and galantamine) were cost-effective 
treatments from a health and social care perspective. Memantine represented 
a cost-effective use of resources only as second choice, when people with 
mild-to-moderate Alzheimer’s disease were intolerant to or have 
contraindications to the use of AChEI. In fact, memantine generated fewer 
quality-adjusted life years (QALYs) at a higher cost. For moderate-to-severe 
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Alzheimer’s disease, memantine appeared to be the most cost-effective 
treatment. 
 
Notwithstanding the high quality of the NICE review, these results have a 
number of limitations. The number of cost-effectiveness studies was relatively 
small (twelve for AChEI, six for memantine). Second, most of these studies 
were funded and/or conducted by the manufacturers of the medications, with 
the attendant potential conflicts of interests. Third, the adaptation of the 
Assessment of Health Economics in Alzheimer’s Disease (AHEAD) model 
used by the NICE analysts was contested by the original developers of the 
model because of the limited amount of data available (Getsios et al., 2007). 
Though the model was based on old data (1988-1999) and collected on a 
small sample, it was argued by NICE to be using the best available data. 
 
A previous literature review of AChIE and memantine (Cappell et al., 2010) 
found donepezil and rivastigmine to be cost-effective (from a societal 
perspective) compared to placebo in mild-to-moderate, and memantine in 
moderate-to-severe Alzheimer’s disease. The authors of this well-conducted 
independent review concluded that this result was largely due to a reduction 
in dependency and an increase in the proportion of carer time free of care-
giving. 
 
Earlier reviews reached slightly different conclusions. For instance, the 
literature review underpinning the 2006 NICE guideline was unable to reach a 
conclusion on the cost-effectiveness of AChEI for mild-to-moderate or 
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memantine for severe Alzheimer’s disease (Loveman et al., 2006). The 
literature review by the Belgian Health Care Knowledge Centre (Hulstaert et 
al., 2009) was similarly cautious due to the quality of available studies. These 
authors argued that health benefits were often gauged by cognition and not as 
functional abilities, which they averred were pivotal in the decision to admit 
someone to institutional care. Hulstaert et al. also highlighted that the 
difference in outcome and cost measures across studies made it difficult to 
pool evidence. They also made the well-known point that it is hard to 
generalise the cost-effectiveness results of a study conducted in one country 
to the context of another. Finally, they noted the pervasive lack of long-term 
data. These same weaknesses were highlighted by Geldmacher (2008) in 
their brief review.  
 
Antipsychotic medications 
 
Antipsychotic medications were recommended in the recent NICE-SCIE 
guidelines for treating non-cognitive symptoms in Alzheimer’s disease, 
vascular dementia, mixed dementia or dementia with Lewy Bodies  with 
severe non-cognitive symptoms, but only after an individual risk-benefit 
assessment due to the possible increased risk of cerebrovascular events 
(NICE-SCIE, 2011). We found no literature reviews on the cost-effectiveness 
of antipsychotic drugs in Alzheimer’s disease. A single study based on a 
Markov model concluded that olanzapine was cost-effective compared to 
doing nothing for the treatment of agitation and psychosis in community-
dwelling individuals with Alzheimer’s disease in the United States (Kirbach et 
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al., 2008). Conversely, a randomized controlled trial found that second-
generation antipsychotics (olanzapine, quetiapine, risperidone) analysed as a 
group were not cost-effective compared to placebo for treating agitation, 
psychosis and aggression in community-dwelling individuals with Alzheimer’s 
disease in the United States (Rosenheck et al., 2007). This well-conducted 
American study (CATIE-D) found that, while health benefits were equivalent, 
health costs were significantly lower in the placebo group. However, the short 
follow-up of 9 months did not allow examination of long-term outcomes or 
costs (e.g., stemming from side-effects or longer-term delays to 
institutionalisation). 
 
Non-pharmacological interventions for individuals with dementia  
 
We found little economic evidence on non-pharmacological interventions for 
individuals with dementia. The evidence can be grouped by intervention type: 
group-based cognitive stimulation, physical exercises programmes and 
tailored activity programmes. 
 
Cognitive stimulation therapy (CST) 
 
Cognitive stimulation therapy (CST) offers ‘activities involving cognitive 
processing; usually in a social context and often group-based, with an 
emphasis on enjoyment of activities’ (NICE-SCIE, 2011, p.49). CST has been 
shown to be effective as primary prevention for older people with good 
cognitive functioning and as secondary prevention for older people with mild-
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to-moderate dementia (Medical Advisory Secretariat, 2008). Literature 
reviews by the Ministry of Health and Long-Term Care in Ontario (Medical 
Advisory Secretariat, 2008) and the Belgian Health Care Knowledge Centre 
(Hulstaert et al., 2009) identified only one randomized controlled trial 
evaluating the cost-effectiveness of a CST programme as secondary 
prevention (Knapp et al., 2006). In this English study, CST was offered to 
people with mild-to-moderate dementia in group sessions run in care homes 
and day centres twice a week for eight weeks. The sessions focused on 
senses, remembering the past, people and objects, and everyday practical 
issues. The authors concluded that CST had the potential to be more cost-
effective than usual care and support through its effects on cognition and 
quality of life. Costs for people receiving CST were not significantly higher 
than costs for usual care. However, findings were weakened by the small 
sample (91 intervention group, 70 control) and the short follow-up period (8 
weeks, and so long-term outcomes are not known. Only people with mild-to-
moderate dementia living in care homes or attending day centres were 
included, which makes it hard to generalise the results to other severity levels 
or settings. In addition, social interaction between group participants could 
have generated the positive outcomes rather than the CST itself. No 
economic evaluation was found for CST as primary prevention intervention 
(Medical Advisory Secretariat, 2008).  
 
Physical exercise programmes 
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Physical exercise programmes have been shown to be effective as primary 
prevention measures for older people with good cognitive functioning and as 
secondary prevention for older people with mild-to-moderate dementia 
(Medical Advisory Secretariat, 2008; Forbes et al., 2008). They have the 
potential to delay onset or slow dementia progression. They are 
recommended in England and Wales as part of a care plan to promote and 
maintain independence for people with dementia (NICE-SCIE, 2011). No 
economic evidence was found.  
 
Tailored activity programme (TAP) 
 
The tailored activity programme approach (TAP) is a home-based intervention 
consisting of eight sessions (six home contacts and two telephone contacts) 
of structured occupational therapy over four months, providing individuals with 
dementia with activities tailored to their cognitive and functional capabilities, 
and to train carers in the use of those activities. It is organised around three 
phases: abilities are evaluated by the occupational therapist; then activities 
are tailored to the capabilities of the individual with dementia and carers are 
instructed on strategies; and finally, once the activities have been mastered, 
occupational therapists help to generalise the strategies to other care 
activities. 
 
A randomised controlled trial conducted in the United States demonstrated 
the cost-effectiveness of TAP compared to usual treatment (Gitlin et al., 
2010), mainly because TAP was able to reduce carer time inputs. However, 
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the study was unclear on how carers chose to spend the non-caregiving time 
that was ‘released’ or whether there were improvements to carer health. 
Moreover, the sample size was small (60 patient-carer pairs, four of whom 
dropped out) and there was no collection of data beyond four months. 
 
Occupational therapy 
 
A randomized controlled study in the Netherlands found that occupational 
therapy at home for community-dwelling people with mild-to-moderate 
dementia was not only cost-effective but also cost-saving when compared to 
usual care (Graff et al., 2008). The intervention consisted of ten one-hour 
sessions at home, delivered over five weeks. The first stage was the 
evaluation of the severity of an individual’s disability and its effects on 
activities of daily living (ADLs), and the selection of which ADLs to aim to 
improve. The second stage was the modification of the home and 
environment, and the teaching of compensatory and environmental strategies. 
Carers were also trained to use effective supervision. The study found that 
cost savings mainly accrued as a result of reductions in informal care, and 
that occupational therapy ‘yielded significant and clinically relevant 
improvements in daily functioning in patients and sense of competence in 
carers’ (Graff et al., 2008, p.7 online). The study has limitations: like many 
studies in this area, it was not possible to make it double-blind, the follow-up 
period was short (3 months, and there were questions about 
representativeness of study participants.  
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Positron emission tomography (PET) 
 
A Belgian study, based on a decision tree design, found that F-fluoro-
deoxyglucose positron emission tomography (FDG PET) was cost-saving 
when added to standard diagnostic approaches because it had the potential 
to delay cognitive decline by allowing the more accurate prescription of 
medications (Moulin-Romsee et al., 2005). 
 
Magnetic resonance imaging (MRI) and neuropsychological testing 
 
Although there is supportive evidence on clinical effectiveness of magnetic 
resonance imaging (MRI) and neuropsychological testing for individuals with 
minor cognitive impairment and mild dementia as diagnostic tools (SBU, 
2008), no cost-effectiveness evidence was found (Hulstaert et al., 2009).   
 
Wandering 
 
A systematic literature review of non-pharmacological interventions to prevent 
wandering in individuals with dementia in comparison to usual care reported 
no relevant cost-effectiveness studies (Robinson et al., 2006; Robinson et al., 
2007).  
 
Ginko biloba 
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No evidence was found on the cost-effectiveness of Ginko biloba as a primary 
or secondary preventive intervention (Hulstaert et al., 2009). 
 
Interventions targeted on carers 
 
Given the key role that unpaid family and other carers play in supporting 
people with dementia, a breakdown in that relationship can often lead to 
short- or long-term admission into a care home or hospital, both of which 
generate high costs for funding bodies, the family or the person with dementia 
themselves. We found economic evidence for only two broad types of 
intervention: respite care and psycho-educational support. 
 
Respite care or short-term breaks 
 
Respite care or short-term breaks may be offered in different forms: day care 
services, in-home respite services, host-family respite, institutional (overnight) 
respite services, respite programmes, multi-dimensional carer-support 
packages and video respite (Arksey et al., 2004). Given this variety it has 
been hard to draw clear conclusions from the available evidence. A report 
from the Ministry of Health and Long-term Care in Ontario (Medical Advisory 
Secretariat, 2008) found only two substantial reviews of the economic 
literature on respite care: a Cochrane review by Lee and Cameron (2004) and 
the above-mentioned review by Arksey and colleagues (2004). 
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In their comprehensive review, Arksey et al. (2004) found economic evidence 
in support of day care. Within the four studies included in their review, two 
‘suggested that day care might be cost-saving’ while the other two ‘suggested 
that day care might provide greater benefits but at a higher cost as compared 
to standard care. All four studies suggested that the benefits of day care might 
be similar or greater than those achieved through standard care’ (p.52). A 
Canadian study that examined the cost-effectiveness of multi-dimensional 
carer-support packages in the 1980s concluded that cost per QALY for the 
support package was quite favourable compared to other health care 
interventions (Drummond et al., 1991). No economic evidence was found for 
in-home respite, host-family respite, institutional or overnight respite, respite 
programmes or video respite. 
 
Psycho-educational support 
 
The Belgian Health Care Knowledge Centre identified only two literature 
reviews on cost-effectiveness of caregiver support (Hulstaert et al., 2009). 
The first was produced by the Swedish Council on Technology Assessment in 
Health Care and based on one short-term study and two long-term economic 
models of non-pharmaceutical interventions for carers (SBU, 2008). Support 
was broadly defined as programmes of counselling, education, emotional 
support, and contact provided to carers. No significant change in cost or 
outcomes was reported when comparison was made to standard care. The 
second review was produced by NICE in collaboration with SCIE: it reached 
no conclusion on the cost-effectiveness of interventions for caregivers of 
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individuals with dementia in comparison with usual care, because of the 
scarcity of evidence and the heterogeneity of the five available economic 
evaluations (NICE-SCIE, 2006). 
 
Befriending 
 
Charlesworth et al. (2008) evaluated a befriending intervention in which 
trained befrienders were matched with carers and given one-to-one emotional 
support in England. Wilson et al. (2009) reported the associated cost-
effectiveness study. The researchers concluded that the befriending 
intervention was neither effective nor cost-effective compared to standard 
care. 
 
Psychosocial intervention 
 
A quasi-experimental study of a psychosocial intervention for family carers in 
Sweden found that counselling sessions and conversation groups resulted in 
significant delays in nursing home placements for people with dementia, 
compared to standard care arrangements (Andren and Elmstahl, 2008). A 
randomised trial was conducted in the United States, evaluating a multi-
component intervention that included ‘modules focusing on information, 
safety, caregiver health and well-being, and behaviour management for the 
care recipient’ (Nichols et al., 2008, p.3 online). Twelve individual sessions 
were delivered in the caregivers’ home (nine sessions) and through telephone 
(three sessions), and supplemented by five telephone-administered support-
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group sessions of five or six careers. The study highlighted a significant 
difference in care-giving hours, each additional hour of care-free time for 
carers costing just under $5 per day or an extra $893 over the 6-month 
period. However, the authors highlighted the short duration of their study (6 
months) compared to the Brodaty and Peters (1991) study in Australia that 
demonstrated cost-savings over 39 months from a multi-component 
residential training programme for carers. 
 
Organization of care and support 
 
Research on the organisation of care and support which has included 
economic evaluation has concentrated on three main areas: direct payments, 
care management, and coordinated responses to co-morbidity. 
 
Direct payments 
 
Direct payments transfer social care funding to service users, who then have 
the opportunity to spend their budgets on a range of services to meet their 
personal (care) needs. Variants of direct payments have been tried in different 
countries as individual budgets, self-directed support, personal budgets, and 
personal health budgets. 
 
There is no evidence on the economic impacts of direct payments or personal 
budgets specifically for people with dementia. The only well-conducted 
economic evaluations for older people – one in England and one in Germany 
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– do not offer especially encouraging support for this organisational 
arrangement. In Germany, Arntz and Thomsen (2011) concluded that cash 
payments crowded-out informal care activity, and did not appear to be cost-
effective. In England, the evaluation of the individual budgets pilot programme 
showed that costs were no different compared to standard care arrangements 
for older people with individual budgets, but outcomes were marginally worse 
(Glendinning et al., 2006). However, the evaluation period of six months may 
have been too short to show expected better outcomes over time. Analysis of 
the impacts of individual budgets on carers of older people suggested better 
outcomes at equivalent costs, compared to standard care and support 
arrangements (Glendinning et al., 2009). 
 
Care management 
 
One review of cost-effectiveness of community-based care management 
(case management or coordinated care/case management) for individuals 
suffering from dementia and their carers was found (Pimouguet et al., 2010). 
Only three randomized controlled studies conducting an economic analysis of 
case management programmes for people with dementia were identified by 
those reviewers. Pimouguet et al. interpreted the evidence as not indicating 
cost-effectiveness, due to the dearth of studies and heterogeneity of the 
populations studied, but our reading of the evidence is different. 
Notwithstanding the scarcity of robust studies, there are a few other well-
conducted studies that demonstrate the impact of care management 
arrangements on delayed institutionalisation, implying economic pay-offs in 
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the United States (Mittelman et al., 2006; Brodaty et al., 2009), in China 
(Chien and Lee, 2008) and in Australia and England (Brodaty et al., 2009).  
 
One study evaluated the cost of a coordinated care management intervention 
for people with dementia living on community settings in the United States 
(Duru et al., 2009). Patients with dementia were assigned a care manager 
responsible for assessing problems at home and then to reassess them every 
six months, developing a care plan, and referring on to primary care and 
community agencies for specific treatment and care services. While 
coordinated care management was not cost-saving compared to standard 
care, it was found to be cost-effective from both payer and social planner 
perspectives because of improvements in patient and carer outcomes, and in 
dementia care quality. 
 
Management of co-morbidity 
 
Individuals with dementia have an elevated risk of co-morbid conditions 
(Duthie et al., 2011), and hence could require more medical or social care. An 
American study showed the higher costs compared with matched individuals 
without dementia (Kuo et al., 2008). The most prevalent co-morbidities were 
psychiatric conditions (depressive, bipolar and delusional disorders), ischemic 
or unspecified stroke, and hip fractures/dislocations. For example, psychiatric 
conditions were five times more prevalent among people with Alzheimer’s 
disease than matched controls, and costs were 1.5 times higher (and even 
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this was an under-estimate due to the inclusion only of costs recorded in the 
Medicare database and medical and pharmaceutical claims). 
 
In the UK, it has been suggested that a quarter of acute NHS hospital beds 
are occupied by people with dementia (Alzheimer's Society, 2009). The 
dementia hospital research in the UK (DEMHOS) highlighted the main causes 
of hospitalization in individuals with dementia as falls (14%), broken/fractured 
hip (12%), urine infection (9%), chest infection (7%) and stroke (7%). Hospital 
stays were longer for people with dementia than for other patients, with 
expected higher costs. Another English study carried out for the National 
Audit Office found that earlier discharge and better management of hip 
fracture in demented patients could save between £64 million and £102 
million a year in England (Henderson et al., 2007; and National Audit Office, 
2007).  
   
Discussion 
 
Summary findings 
 
Our literature review synthesised the economic evidence on dementia care. 
There is more cost-effectiveness evidence on pharmacological therapies than 
for any other types of intervention, with the largest collection of evidence 
relating to acetylcholinesterase inhibitors (AChIE) and memantine. In 
particular, AChIE for mild-to-moderate disease and memantine for moderate-
to-severe disease were found to be cost-effective. The much smaller body 
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evidence on non-pharmacological treatments (cognitive stimulation therapy, 
tailored activity programme and occupational therapy) was harder to interpret. 
 
Evidence on support for family and other unpaid carers was limited and 
confined to a narrow range of options: day care, psycho-educational 
interventions and befriending. Similarly, there was little cost-effectiveness 
evidence on strategies to alter the organisation of care and support: some 
evidence on direct payments and some on care/case management. Evidence 
in the latter area suggested long-term cost-effectiveness. The small body of 
evidence on management of co-morbidity in people with dementia pointed to 
potentially sizeable savings and cost-effectiveness gains. 
 
No evidence were found on primary prevention of dementia or action to delay 
its onset, and on end-of-life care for people with dementia except for one 
study of costs (McCrone, 2009). 
 
Limitations 
 
While database searches covered all countries, websites searches were 
confined to the United Kingdom. Although we did not expect to find many 
studies from governmental and non-governmental websites in other countries, 
we were unable to check. Second, the quality of some literature reviews found 
was low and none of presented findings was supported by meta-analysis due 
to the paucity and heterogeneity of available studies. Third, for the same 
reason we were unable to perform a meta-analysis on included studies. 
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Barriers to achieving cost-effectiveness 
 
From this review we can identify a number of barriers to achieving better 
value for money in dementia care. One obvious barrier is the scarcity and low 
methodological quality of the available studies, making it difficult to draw 
conclusions with confidence. Among those limitations is the short time frame 
adopted for measuring most outcomes and costs.  
 
Second, generalisation from the available evidence is hindered by both the 
heterogeneity of the populations studied (in terms of severity, co-morbidity, 
care settings) and familiar inter-country differences in organisation, funding 
and incentives in health and social care systems.  
 
Third, many studies adopt a narrow perspective when measuring cost, looking 
only at health care. Given the pivotal roles of family and other carers in 
dementia care, a broader societal perspective is generally needed if decision-
makers are to understand the wide range of potential economic impacts, 
including the opportunity costs of carer inputs and the impacts of caring on 
their own health and wellbeing.  
 
Fourth, even when robust evidence is available and relevant, there is an 
apparent reluctance to implement it by adjusting the treatment, care and 
support offered. For instance, even though cognitive stimulation therapy is 
supported by fairly good effectiveness and cost-effectiveness evidence, albeit 
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over relatively short periods, only 10% of the primary care trusts and mental 
health trusts in England is commissioning or delivering such therapy (data 
from a FOI request sent to Trusts and passed on to us). 
 
Fifth, while people with dementia usually experience deteriorations in both 
health and capacity for self-care, and hence need both health and social care 
support, these services are often delivered by different providers and funded 
from different budgets, and poor coordination – most damagingly in the form 
of cost-shifting and ‘problem-dumping’ – will be a source of inefficiency. The 
need for better coordination is heightened at a time of macroeconomic 
austerity – with attendant budget cuts – but is arguably harder to achieve in 
such a context. Some form of self-directed care, for example personal 
budgets held by carers, might offer a solution to this ‘silo budget’ problem. 
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Figure 1: Flow chart of study selection process 
 
N=2731 
potentially relevant references identified from electronic 
databases (N=2686) and websites (N=45);  
eligible for screening by title/abstract 
N=329 
potentially relevant references; 
eligible for screening by full-text 
N=56 
relevant references; 
eligible for data extraction 
N=1976 
references excluded after 
screening by title/abstract 
N=258 
references excluded after 
screening by full-text 
N=71 
references excluded 
because full-text not found 
N=426 
references excluded as 
duplicates 
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APPENDIX 
 
Search strategy 
 
PubMed 
"Dementia"[Mesh] AND (("Costs and Cost Analysis"[Mesh] OR 
"Hospitals"[Mesh]) OR "Home Care Services"[Mesh]) 
Limits: Publication Date from 2005/01/01 to 2011/12/31 
 
Embase (OvidSP) 
dementia/ AND ("cost"/ OR hospital/ OR home care/) 
Limits: Publication Date from 2005 to 2011 
 
PsycINFO (OvidSP) 
(exp dementia/) AND ((exp "costs and cost analysis"/) OR hospitals/ OR 
home care/) 
Limits: Publication Date from 2005 to 2011 
 
EconLit (EBSCO) 
(Dementia* OR Alzheimer*) AND (Economic* OR cost OR costs OR costing 
OR Cost-benefit OR Cost-utility OR Cost-effectiveness OR Expenditure* OR 
commissioning OR spending OR Budget* OR savings OR financ* OR pay-off* 
OR Payer OR “Third-party payer” OR “health insurance” OR “health 
insurances” OR “psychiatric insurance” OR “psychiatric insurances” OR 
“catastrophic health insurance” OR “catastrophic health insurances” OR “high-
deductible health plan” OR “high-deductible health plans” OR Medicare OR 
Medicaid OR Medigap OR Medisave OR Medishield OR Medifund OR 
Eldershield OR Fee* OR “fee-for-service” OR “fee for service” OR “hospital 
charge” OR “hospital charges” OR “out-of-pocket” OR “co-payment” OR 
“copayment” OR “co-insurance” OR “coinsurance” OR “user charge” OR “user 
charges” OR deductibl* OR reimbursement* OR “diagnosis-related group” OR 
“diagnosis-related groups” OR “diagnosis related group” OR “diagnosis 
related groups” OR “Medical Savings Account” OR “Medical Savings 
Accounts” OR “social security” OR “social care” OR “disability claim” OR 
“disability claims” OR “disability benefit” OR “disability benefits” OR “disability 
allowance” OR “disability allowances” OR “disability living allowance” OR 
“disability living allowance” OR “carer’s allowance” OR “carer’s allowance” OR 
“attendance allowance” OR “attendance allowances” OR “self directed 
support” OR “self-directed support” OR “direct payment” OR “direct payments” 
OR “cash payment” OR “cash payments” OR housing OR Institutionalisation* 
OR Institutionalization* OR “nursing home” OR “nursing homes” OR “skilled 
nursing unit” OR “skilled nursing units” OR “care home” OR “care homes” OR 
“rest home” OR “rest homes” OR “convalescent home” OR “convalescent 
homes” OR “medicalised home” OR “medicalised homes” OR “medicalized 
home” OR “medicalized homes” OR “home care” OR “homecare” OR “respite 
care” OR “residential care” OR “community care” OR “community-based care” 
OR “long term care” OR “long-term care” OR “long term support” OR “long-
term support” OR “assisted living” OR Employment* OR Income* OR salary 
OR salaries OR Wage* OR “career mobility” OR (resource* N3 use*) OR 
(resource* N3 utili*) OR (resource* N3 consum*) OR (service* N3 use*) OR 
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(service* N3 utili*) OR (service* N3 consum*) OR hospitali* OR (inpatient N3 
use*) OR (inpatient N3 utili*) OR (inpatient N3 consum*) OR (in-patient N3 
use*) OR (in-patient N3 utili*) OR (in-patient N3 consum*) OR (hospital N3 
use*) OR (hospital N3 utili*) OR (hospital N3 consum*) OR (healthcare* N3 
use*) OR (healthcare* N3 utili*) OR (healthcare*N3 consum*) OR (health 
care* N3 use*) OR (health care* N3 utili*) OR (health care* N3 consum*)) 
Limits: Publication Date from 2005/01/01 to 2011/12/31 
 
The Cochrane Library (Cochrane Reviews) 
(MeSH descriptor Dementia explode tree 2) AND (Economic* OR cost OR 
costs OR costing OR Cost-benefit OR Cost-utility OR Cost-effectiveness OR 
Expenditure* OR commissioning OR spending OR Budget* OR savings OR 
financ* OR pay-off* OR Payer OR Medicare OR Medicaid OR Medigap OR 
Medisave OR Medishield OR Medifund OR Eldershield OR Fee* OR fee-for-
service OR out-of-pocket OR co-payment OR copayment OR co-insurance 
OR coinsurance OR deductibl* OR reimbursement* OR housing OR 
Institutionalization* OR Institutionalisation* OR homecare OR Employment* 
OR Income* OR salary OR salaries OR Wage* OR insurance* OR high-
deductible) OR (fee for service) OR (hospital charge) OR (hospital charges) 
OR (user charge) OR (user charges) OR (diagnosis-related group) OR 
(diagnosis-related groups) OR (diagnosis related group) OR (diagnosis 
related groups) OR (Medical Savings Account) OR (Medical Savings 
Accounts) OR (social security) OR (social care) OR (disability claim) OR 
(disability claims) OR (disability benefit) OR (disability benefits) OR (disability 
allowance) OR (disability allowances) OR (disability living allowance) OR 
(disability living allowance) OR (carer's allowance) OR (carer's allowance) OR 
(attendance allowance) OR (attendance allowances) OR (self directed 
support) OR (self-directed support) OR (direct payment) OR (direct payments) 
OR (cash payment) OR (cash payments) OR (nursing home) OR (nursing 
homes) OR (skilled nursing unit) OR (skilled nursing units) OR (care home) 
OR (care homes) OR (rest home) OR (rest homes) OR (convalescent home) 
OR (convalescent homes) OR (medicalised home) OR (medicalised homes) 
OR (medicalized home) OR (medicalized homes) OR (home care) OR 
(respite care) OR (residential care) OR (community care) OR (community-
based care) OR (long term care) OR (long-term care) OR (long term support) 
OR (long-term support) OR (assisted living) OR (career mobility) OR 
(resource* AND use*) OR (resource* AND utili*) OR (resource* AND 
consum*) OR (service* AND use*) OR (service* AND utili*) OR (service* AND 
consum*) OR hospitali* OR (inpatient AND use*) OR (inpatient AND utili*) OR 
(inpatient AND consum*) OR (in-patient AND use*) OR (in-patient AND utili*) 
OR (in-patient AND consum*) OR (hospital AND use*) OR (hospital AND 
utili*) OR (hospital AND consum*) OR (healthcare* AND use*) OR 
(healthcare* AND utili*) OR (health care* AND consum*) OR (health care* 
AND use*) OR (health care* AND utili*) OR (health care* AND consum*)) 
Limits: Publication Date from 2005 to 2011 
 
Centre for Reviews and Dissemination (DARE, NHS EED, HTA) 
(MeSH Dementia EXPLODE 2) AND (Economic* OR cost OR costs OR 
costing OR Cost-benefit OR Cost-utility OR Cost-effectiveness OR 
Expenditure* OR commissioning OR spending OR Budget* OR savings OR 
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financ* OR pay-off* OR Payer OR Medicare OR Medicaid OR Medigap OR 
Medisave OR Medishield OR Medifund OR Eldershield OR Fee* OR fee-for-
service OR out-of-pocket OR co-payment OR copayment OR co-insurance 
OR coinsurance OR deductibl* OR reimbursement* OR housing OR 
Institutionalization* OR Institutionalisation* OR homecare OR Employment* 
OR Income* OR salary OR salaries OR Wage* OR insurance* OR high-
deductible OR “fee for service” OR “hospital charge” OR “hospital charges” 
OR “usercharge” OR “user charges” OR “diagnosis-related group” OR 
“diagnosis-related groups” OR “diagnosis related group” OR “diagnosis 
related groups” OR “Medical Savings Account” OR “Medical Savings 
Accounts” OR “social security” OR “social care” OR “disability claim” OR 
“disability claims” OR “disability benefit” OR “disabilit benefits” OR “disability 
allowance” OR “disability allowances” OR “disability living allowance” OR 
“disability living allowance” OR “carer’s allowance” OR “carer’s allowance” OR 
“attendance allowance” OR “attendance allowances” OR “self directed 
support” OR “self-directed support” OR “direct payment” OR “direct payments” 
OR “cash payment” OR “cash payments” OR “nursing home” OR “nursing 
homes” OR “skilled nursing unit” OR “skilled nursing units” OR “care home” 
OR “care homes” OR “rest home” OR “rest homes” OR “convalescent home” 
OR “convalescent homes” OR “medicalised home” OR “medicalised homes” 
OR “medicalized home” OR “medicalized homes” OR “home care” OR 
“respite care” OR “residential care” OR “community care” OR “community-
based care” OR “long term care” OR “long-term care” OR “long term support” 
OR “long-term support” OR “assisted living” OR “career mobility” OR ( 
resource* AND use* ) OR ( resource* AND utili* ) OR ( resource* AND 
consum* ) OR ( service* AND use* ) OR ( service* AND utili* ) OR ( service* 
AND consum* ) OR hospitali* OR ( inpatient AND use* ) OR ( inpatient AND 
utili* ) OR ( inpatient AND consum* ) OR ( in-patient AND use* ) OR ( in-
patient AND utili* ) OR ( in-patient AND consum* ) OR ( hospital AND use* ) 
OR ( hospital AND utili* ) OR ( hospital AND consum* ) OR ( healthcare* AND 
use* ) OR ( healthcare* AND utili* ) OR ( health AND care* AND consum* ) 
OR ( health AND care* AND use* ) OR ( health AND care* AND utili* ) OR ( 
health AND care* AND consum* ))  
Limits: Publication Date from 2005 to 2011 
 
Websites 
Google advanced search: dementia OR "Alzheimer’s disease" OR "vascular 
dementia" cost OR hospital OR "home care" site:[website address] 
 
Search results 
 
Source Number of references 
  
Databases 
 
PubMed 947 
Embase (OvidSP) 1138 
PsycINFO (OvidSP) 308 
EconLit (EBSCO) 28 
The Cochrane Library (Cochrane Reviews) 81 
Centre for Reviews and Dissemination  (DARE, 184 
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NHS, EED, HTA) 
Total (databases) 2686 
  
Websites  
National Institute for Clinical Excellence 3 
Social Care Institute for Excellence 1 
National Audit Office 6 
Royal College of Psychiatrists 0 
Royal College of General Practitioners 0 
Alzheimer’s Society 26 
Kings Fund 3 
Carers UK 1 
Mental Health Foundation 3 
Age UK (formerly Age Concern & Help the Aged) 2 
Bradford Dementia Group (at Bradford 
University) 
0 
Total (websites) 45 
  
Total before screening 2731 
 
